Surrozen, Inc. (SRZN) AI Stock Analysis

Surrozen, Inc. is a biotechnology company dedicated to the discovery and advancement of drug candidates that selectively modulate the Wnt pathway to facilitate tissue repair and regeneration. Its approach centers on developing tissue-specific antibodies for conditions affecting organs such as the liver, intestine, retina, cornea, lung, kidney, skin, pancreas, and central nervous system. The pipeline is led by SZN-043, a tissue-specific R-spondin mimetic targeting severe liver diseases, and SZN-1326, a bi-specific antibody designed to modulate Wnt signaling in intestinal crypts. Founded in 2015, the company is based in South San Francisco, California.

Surrozen's revenue fell from $12.5M in FY2022 and FY2023 to $10.7M in FY2024 and $3.5M in FY2025, resulting in a 3-year revenue CAGR of -34.7%. Net losses expanded from -$27.7M in FY2022 to -$43.0M in FY2023, -$63.6M in FY2024, and -$242.0M in FY2025, when operating margin reached -1210.6%. For the trailing twelve months ended June 30, 2026, revenue stood at $11.5M with an operating margin of -207.4%. In the latest quarter ended June 30, 2026, quarterly revenue increased 408.6% year-over-year, while quarterly earnings declined 37.0%.

As of June 30, 2026, Surrozen held $102.0M in cash and short-term investments against $6.3M in total debt, creating a net cash position of $95.7M. The company reported total assets of $115.6M, a current ratio of 12.14, and negative shareholders' equity of -$218.7M. In FY2025, operating cash flow was -$30.2M and free cash flow was -$30.4M. Capital expenditures reached $128,000 in FY2025, while share issuances raised $198,000, following an 891.0% increase in share count over 5 years.

Surrozen trades at a price-to-sales ratio of 23.9x, compared to the median of 4.1x for its US-listed Healthcare peers. Its enterprise value-to-EBITDA stands at 0.7x, below the peer group median of 12.0x, based on an enterprise value of $94.2M and a market capitalization of $275.5M. The stock closed at $23.44 on October 16, 2026, trading 5.3% below its 200-day average. Over the past year, the stock returned 72.4%, outperforming the S&P 500 return of 16.8%, though its 5-year return of -75.3% lagged the index return of 83.0%.

Surrozen has 6 Strong Buy ratings from analysts, with 0 Buy, Hold, Sell, or Strong Sell ratings. The mean price target is $48.40, representing an upside of 106.5% from the last close of $23.44. For the fiscal year ending December 31, 2026, consensus estimates project an EPS of -$9.14 on revenue of $10.7M. For the next fiscal year, 3 analysts project revenue to fall to $1.5M alongside an EPS of -$4.19. Surrozen beat EPS estimates in 1 of the last 4 quarters, and its next earnings date is November 6, 2026.

This page is an AI-written research summary of Surrozen, Inc. (SRZN). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: SRZN income statement, SRZN balance sheet, SRZN key metrics, SRZN analyst forecast, SRZN chart. See the SRZN stock overview for the latest quote and news.